Author/Authors :
Federico, Alessandro Second University of Naples - Department of Clinical and Experimental Medicine, Gastroenterology Unit, Italy , Sgambato, Dolores Second University of Naples - Department of Clinical and Experimental Medicine, Gastroenterology Unit, Italy , Cotticelli, Gaetano Second University of Naples - Department of Clinical and Experimental Medicine, Gastroenterology Unit, Italy , Gravina, Antonietta Gerarda Second University of Naples - Department of Clinical and Experimental Medicine, Gastroenterology Unit, Italy , Dallio, Marcello Second University of Naples - Department of Clinical and Experimental Medicine, Gastroenterology Unit, Italy , Beneduce, Filippo Second University of Naples - Department of Clinical and Experimental Medicine, Gastroenterology Unit, Italy , Ruocco, Eleonora Second University of Naples - Department of Dermatology, Italy , Romano, Marco Second University of Naples - Department of Clinical and Experimental Medicine, Gastroenterology Unit, Italy , Loguercio, Carmela Second University of Naples - Department of Clinical and Experimental Medicine, Gastroenterology Unit, Italy
Abstract :
Introduction: Dermatological adverse events are an existing concern during treatment of hepatitis C virus infection. Peginterferon/ribavirin treatment is associated with well-characterized dermatological lesions tending towards a uniform entity of dermatitis. New telaprevir- or boceprevir-based triple-therapy has led to significant improvements in sustained virological response rates, although associated with an increase in cutaneous adverse events compared peginterferon/ribavirin alone.Case Presentation: We report a case of a patient who discontinued telaprevir because of severe skin eruptions and who, during ribavirin and interferon treatment, after a period free of skin lesions, developed new dermatological lesions different than those experienced during telaprevir treatment.Conclusions: Several adverse effects are associated to anti-HCV drugs, hence appropriate skin care management and follow-up are very important. A careful anamnesis before the initiation of triple therapy is necessary to identify previous dermatological diseases that could increase skin adverse effects incidence.
